Aberdeen Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Aberdeen Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.7M	Hold	820,395	–	–	0.04%	333
2026 Q1	$29.8M	Buy	820,395 +145,862	+22%	+$6.51M	0.05%	308
2025 Q4	$31.4M	Buy	674,533 +334,584	+98%	+$14.9M	0.05%	310
2025 Q3	$14.2M	Buy	339,949 +59,602	+21%	+$1.91M	0.02%	537
2025 Q2	$8.06M	Buy	280,347 +72,288	+35%	+$2.23M	0.01%	644
2025 Q1	$6.98M	Buy	208,059 +164,670	+380%	+$6.15M	0.01%	638
2024 Q4	$2.22M	Buy	43,389 +7,922	+22%	+$443K	﹤0.01%	753
2024 Q3	$1.81M	Sell	35,467 -30,729	-46%	-$1.58M	﹤0.01%	763
2024 Q2	$2.96M	Sell	66,196 -35,000	-35%	-$1.62M	0.01%	710
2024 Q1	$4.74M	Hold	101,196	–	–	0.01%	675
2023 Q4	$3.6M	Buy	+101,196	New	+$3.1M	0.01%	722

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's CRNX Position: Q2 2026 in Review

Aberdeen Group held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 820,395 shares worth $30.7M. The position accounts for 0.04% of the portfolio, ranked #333.

Aberdeen Group first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $31.4M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Aberdeen Group held 820,395 shares of Crinetics Pharmaceuticals worth $30.7M as of Q2 2026.
Aberdeen Group left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #333 holding.
Aberdeen Group first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Aberdeen Group's Crinetics Pharmaceuticals position peaked at $31.4M in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.